TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

Haematologica

Volumn 94, Issue 12, 2009, Pages 1676-1681

  Kosmider, Olivier ^a,b,c,d   Gelsi Boyer, Véronique ^e   Ciudad, Marion ^f,g   Racoeur, Cindy ^f,h   Jooste, Valérie ^f,g   Vey, Norbert ^e   Quesnel, Bruno ⁱ   Fenaux, Pierre ^j,k   Bastie, Jean Noël ^f,h   Beyne Rauzy, Odile ^l   Stamatoulas, Aspasia ^m   Dreyfus, François ^a,b,c,d   Ifrah, Norbert ⁿ   De Botton, Stéphane ^b   Vainchenker, William ^b   Bernard, Oliver A ^b   Birnbaum, Daniel ^e   Fontenay, Michaëla ^a,b,c,d   Solary, Eric ^b,f,h  

^a Hôpital Cochin ^*  (France)

^b INSERM   (France)

^c INSTITUT COCHIN   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f Chu   (France)

^g UNIVERSITÉ DE BOURGOGNE   (France)

^h HÔPITAL DU BOCAGE   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j UNIVERSITÉ PARIS 13   (France)

^k Institut Gustave Roussy   (France)

^l CHU PURPAN   (France)

^m ROUEN UNIVERSITY HOSPITAL   (France)

ⁿ ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Chronic myelomonocytic leukemia; Mutation; TET2 gene

Indexed keywords

GENE PRODUCT; TEN ELEVEN TRANSLOCATION 2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLAST CELL; BLOOD CELL; BONE MARROW CELL; CANCER SURVIVAL; CELL COUNT; CHRONIC MYELOMONOCYTIC LEUKEMIA; EXON; FEMALE; FRAMESHIFT MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MONOCYTE; NONSENSE MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS;

EID: 73149094518     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.011205     Document Type: Article

References (24)

1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835-49.
2. Gelsi-Boyer V, Trouplin V, Adélaïde J, Aceto N, Remy V, Pinson S, et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer 2008;8:299.
3. Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 2009;23:1426-31.
4. Gelsi-Boyer V, Trouplin V, Adelaïde J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009;145:788-800.
5. Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008;68:10349-57.
6. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009;113:6182-92.
7. Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood 2009;113:1749-55.
8. Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 2008;22:1308-19.
9. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-11.
10. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009;23:900-4
11. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343-5.
12. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009;113:6403-10.
13. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144-7.
14. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301.
15. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838-42.
16. Mohamedali AM, Smith AE, Gaken J, Lea NC, Mian SA, Westwood NB, et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009;27:4002-6.
17. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, et al. TET2 mutation is an independent favourable prognostic factor in myelodyplastic syndromes. (MDSs) Blood 2009;114:3285-91.
18. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007;110:375-9.
19. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by the MLL fusion partner TET1. Science 2009;324:930-5.
20. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002;30:229-36.
21. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002;62:4075-80.
22. Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003;17:637-41.
23. Burmeister T, Meyer C, Schwartz S, Hofmann J, Molkentin M, Kowarz E, et al. The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia - results from the GMALL study group. Blood 2009;113:4011-5.
24. Morgan AR, Hamilton G, Turic D, Jehu L, Harold D, Abraham R, et al. Association analysis of 528 intragenic SNPs in a region of chromosome 10 linked to late onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2008;147:727-31.